



Company Announcement no. 21/2009
Interim report for the 9 Months Ended September 30, 2009

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, November 11, 2009

LifeCycle Pharma Announces Result for the First Nine Months of 2009 and Improves Once Again the Full Year Outlook

Highlights

- LifeCycle Pharma A/S (OMX:LCP) today announced the Interim Report for the 9 months ended September 30, 2009 and reported in line with expectations a net loss of DKK 211.2 million for the first nine months of 2009, compared to a net loss of DKK 69.1 million for the same period in 2008. During the first nine months of 2009 LCP recognized DKK 2.3 million in revenues compared to DKK 165.3 million in the same period of 2008. Revenue in 2008 includes DKK 152 million up-front payment in connection with the sale of the future royalty stream from Fenoglide®.
- For the first nine months of 2009, LCP's research and development costs amounted to DKK 164.4 million compared to DKK 192.2 million during the same period in 2008.
- On September 30, 2009, LCP had cash and cash equivalents of DKK 392.1 million.
- Positive LCP-Tacro™ results have been obtained from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro™ tablets in stable liver transplant patients. These new data demonstrated that LCP-Tacro™ tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf®.
- On August 31, 2009, LCP announced that the Board of Directors of LCP and Jim New, President & CEO had agreed to terminate the contract with Jim New. Until a new CEO has been identified, Paul Edick, Chairman of the Board of LCP, and Dr. Thomas Dyrberg, Deputy Chairman of the Board, will, upon request from the Board of Directors, assume such specific assignments for the Company, which are necessary to ensure LCP's continual and uninterrupted business together with the management of LCP. The search for a new CEO is ongoing.
- The recruitment of patients is progressing in the Phase 3 study for LCP-Tacro™ in stable kidney patients and now approximately 80% are enrolled compared to 50% enrolled in the previous quarter. At the same time the preparation of the phase 3 protocol for LCP-Tacro™ in de novo kidney patients is in its final stage and is expected to be submitted to the U.S. Food and Drug Administration (FDA) before the year-end.
- The full year outlook for 2009 is improved once again. LCP now expects an operating loss in the range of DKK 290 - 310 million and a net loss in the range of DKK 280 - 300 million. LCP's cash position is expected to be in the range of DKK 300 - 330 million at year-end 2009.

A conference call will be held tomorrow, November 12, 2009 at 2.30 PM CET (Denmark). Please refer to page 7 for further details.



Outlook for 2009

The full year outlook for 2009 is improved. LCP now expects an operating loss in the range of DKK 290 - 310 million and a net loss in the range of DKK 280 - 300 million.

LCP's earlier outlook for 2009, which was announced in connection with LCP's Interim Report on August 20, 2009, projected an operating loss of DKK 350 - 380 million and a net loss in the range of DKK 330 - 360 million.

The improvement is a result of continuous optimization of the cost base as well as postponement in timing of the costs associated with the LCP-Tacro™ Phase 3 development program due to changes in regulatory guidelines influencing the design of this program.

Cash and cash equivalents are expected to be in the range of DKK 300 - 330 million at December 31, 2009, and are expected to sustain operations into 2011. This compares with expectations of DKK 250 - 300 million announced in connection with LCP's Interim Report on August 20, 2009.

Research & Development Update

LCP-Tacro™ in liver patients

As announced on August 20, 2009, LCP has received positive interim results of Phase 2 pharmacokinetic clinical studies involving 58 patients in de novo liver transplant patients. These data confirm the previous clinical results with LCP-Tacro™ in stable kidney and liver transplant patients announced in March and July 2008, respectively, as well as data announced in April 2009 for de novo kidney patients. The results demonstrate that over the first 14 days of the pharmacokinetic study stage within the early post-operative period following a liver transplant, LCP-Tacro™ tablets can be safely and efficaciously administered once-daily to de novo liver transplant patients.

LCP completed a one year Phase 2 extension study in stable liver patients later in September this year. On that basis, LCP will initiate discussions with the FDA for the design and timing of the pivotal Phase 3 program in de novo liver patients.

LCP-Tacro™ in kidney patients

The current Phase 3 clinical study in stable patients is continuing to recruit patients in study centers in both U.S. and in Europe. All contracts with the 52 centers (33 in the U.S. and 19 in Europe) have been concluded. The recruitment during the last quarter has been according to the plan announced in connection with the half year results for 2009, and the enrollment is now approximately 80% complete. The study is still expected to be completed in the first quarter of 2011. Based on the positive interim data for the Phase 2 pharmacokinetic clinical studies in de novo kidney transplant patients LCP continues its dialogue with the FDA with a view to submit a final Phase 3 protocol during the fourth quarter of 2009 as previously communicated.

The upcoming Phase 3 studies in de novo kidney transplant patients will run in parallel with LCP's current ongoing Phase 3 studies in stable kidney transplant patients.



Key Figures	YTD 2009 DKK'000	YTD 2008 DKK'000	Q3 2009 DKK'000	Q3 2008 DKK'000	Year 2008 DKK'000
Income Statement					
Revenue	2,294	165,313	447	154,433	170,122
Research and development costs	(164,400)	(192,191)	(43,986)	(69,738)	(270,875)
Administrative expenses	(47,668)	(55,025)	(14,330)	(18,626)	(73,311)
One-off restructuring cost	(9,489)	-	(9,489)	-	-
Operating loss	(219,263)	(81,903)	(67,358)	66,069	(174,064)
Net financial income / (expenses)	8,024	12,778	394	5,150	24,285
Net loss for the period	(211,239)	(69,125)	(66,964)	71,219	(149,779)
Balance Sheet					
Cash and cash equivalents	392,133	666,895	392,133	666,895	600,130
Total assets	444,915	708,915	444,915	708,915	646,293
Share capital	56,568	56,288	56,568	56,288	56,288
Total equity	373,583	648,456	373,583	648,456	572,323
Investment in property, plant and equipment	10,555	5,212	890	1,205	6,571
Cash Flow Statement					
Cash flow from operating activities	(194,356)	(34,054)	(44,714)	80,141	(102,560)
Cash flow from investing activities	(10,507)	(5,212)	(843)	(1,205)	(6,628)
Cash flow from financing activities	2,041	375,290	(446)	463	373,637
Cash and cash equivalents at period end	392,133	666,895	392,133	666,895	600,130
Financial Ratios					
Basic and diluted EPS	(3.75)	(1.48)	(1.19)	1.27	(3.06)
Weighted average number of shares	56,401,877	46,561,782	56,467,878	56,135,241	49,006,500
Average number of employees (FTEs)	97	105	88	113	102
Assets/equity	1.19	1.09	1.19	1.09	1.13

The interim report is unaudited.

Revenue

During the first nine months of 2009 LCP recognized DKK 2.3 million in revenues compared to DKK 165.3 million in the same period of 2008. Revenue consists of payments under LCP's collaboration agreements. Revenue in 2008 includes DKK 152 million up-front payment in connection with the sale of the future royalty stream from Fenoglide®.

Research and Development Costs

For the first nine months of 2009, LCP's research and development costs amounted to DKK 164.4 million compared to DKK 192.2 million during the same period in 2008. Research and development costs in the third quarter of 2009 were realized at a lower level compared to the previous sequential quarter, with DKK 44.0 million in the third quarter of 2009 compared to DKK 57.6 million in the second quarter of 2009. This decrease is due to fluctuations in activity related to the ongoing Phase 3 trial regarding LCP-Tacro™ (kidney).



Administrative Expenses

For the first nine months of 2009, LCP's administrative cost amounted to DKK 47.7 million compared to DKK 55.0 million during the same period in 2008. Administrative costs in the third quarter of 2009 were realized at a lower level compared to the previous sequential quarter, with DKK 14.3 million in the third quarter of 2009 compared to DKK 16.4 million in the second quarter of 2009. The decrease in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the reduction in force, which was executed in August 2009.

One-off restructuring cost

One-off restructuring cost mainly includes provisions for future salary payments to former employees in connection with the reduction in force that was executed in August 2009.

Share-based Compensation Costs

For the first nine months of 2009, a total of DKK 10.4 million was recognized as share-based compensation. The cost is included in R&D and G&A. The comparable cost for 2008 was DKK 12.5 million. In the third quarter of 2009, a total of 887,644 warrants have been cancelled, a total of 129,490 warrants have been exercised at an average exercise price of DKK 6.48, and a total of 135,000 warrants were granted to members of the Board of Directors at a strike price of DKK 9.55 each.

As of September 30, 2009, a total of 4,138,583 warrants were outstanding at an average strike price of DKK 22.4. Members of the Board of Directors held 350,667 warrants at an average strike price of DKK 21.8. Members of Executive Management held 257,572 warrants at an average strike price of DKK 26.9, while other current and former employees held 3,530,344 warrants at an average strike price of DKK 22.1.

Please refer to LCP's latest annual report for additional details regarding LCP's warrant programs.

Operating Loss

LCP's operating loss for the first nine months of 2009 was DKK 219.3 million compared to DKK 81.9 million in the corresponding period of 2008.

Financial Income

During the first nine months of 2009, LCP recognized net financial income of DKK 8.0 million compared to DKK 12.8 million in the first nine months of 2008.

Net Loss

LCP's net loss for the first nine months of 2009 was DKK 211.2 million compared to DKK 69.1 million in the corresponding period of 2008.

Cash Flow

As per September 30, 2009, the balance sheet reflects cash and cash equivalents to DKK 392.1 million compared to DKK 600.1 million as per December 31, 2008. This represents a decrease of DKK 208.0 million related to LCP's operating activities for the period.

Balance Sheet

As per September 30, 2009, total assets were DKK 444.9 million compared to DKK 646.3 million at the end of 2008.



Shareholders' equity equalled DKK 373.6 million as of September 30, 2009, compared to DKK 572.3 million at the end of 2008.

Accounting Policies

The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of LCP's annual report 2008.

LCP has implemented the following standards and interpretations as of January 1, 2009:

- IFRS 8, "Operating Segments"
- IAS 1, "Presentation of Financial Statements" (amendment)
- IFRS 2, "Share-based payment" (amendment)

The standards and interpretations have not changed the recognition, measurement and presentation in the financial statements, except that comprehensive income has been included in the income statement. The implementation has not had any material effect on the numbers or the presentation hereof. The interim report is unaudited.

The line "one-off restructuring cost" includes major restructuring costs, mainly future salary to former employees, and is shown separately to facilitate the comparability of income statement and to provide a better picture of the operational result.

Financial Review

LCP publishes its financial statements in Danish Kroner (DKK), which is the functional currency of LCP and the group. Solely for the convenience of the reader, this Interim Report contains a conversion of certain DKK amounts into Euro (EUR) at a specified rate. These converted amounts should not be construed as representations that the DKK amounts actually represent such EUR amounts or could be converted into EUR at the rate indicated or at any other rate. Unless otherwise indicated, conversion herein of financial information into EUR has been made using the Danish Central Bank's spot rate on September 30, 2009, which was EUR 1.00 = DKK 7.4443.

Grant of Warrants

At a board meeting held on November 11, 2009, the Board of Directors decided to issue 218,000 warrants to employees of the Company and the Company's US subsidiary. Out of the total granted warrants, William J. Polvino, Chief Operating Officer was granted 150,000 warrants.

Each warrant entitles the holder to subscribe one share of nominal DKK 1 in LCP against a cash contribution equal to the closing price of LCP's shares at the NASDAQ OMX Copenhagen on November 12, 2009, thus ensuring that the exercise price reflects the fair market price per share following the disclosure of the interim report for the first nine months of 2009.

By application of the Black-Scholes formula, the market value of the warrant program can be calculated as DKK 2.9 per warrant assuming an exercise price of DKK 7.00, equal to the closing price of LCP's share at the NASDAQ OMX Copenhagen on November 11, 2009, based on an interest rate of 2.67% and a volatility of LCP's shares set to 48%.

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



From January 1, 2009, the volatility is based on LCP's historical share prices since its Initial Public Offering in November 2006.

Financial calendar for 2010

February 24, 2010	Annual report 2009
April 21, 2010	Annual General Meeting
May 12, 2010	Interim report for the first three months of 2010
August 18, 2010	Interim report for the first six months of 2010
November 10, 2010	Interim report for the first nine months of 2010



Conference Call

Tomorrow, November 12, 2009, LCP's Management will host a conference call, at 2:30 PM CET (Denmark); 1:30 PM GMT (London), 8:30 AM ET (New York), 05:30 AM PT (San Francisco), To access the call, please dial one of the following numbers: +1 866 966 5335 (US), +44 (0) 2030 032 666 (UK), +45 (0) 32 729 273 (DK).

If you cannot access the conference call by mobile phone this could be caused by some mobile providers blocking the mobile phone from getting access to certain numbers i.e. toll-free numbers. Therefore please use the DK number (+45 (0) 32 729 273) or the UK number (+44 (0) 2030 032 666) as these numbers are not toll-free numbers.

An audio replay of the conference call will be available on www.lcpharma.com from tomorrow Thursday, November 12, 2009 at 5:30 PM CET (Denmark); 4:30 PM GMT (London), 11:30 PM ET (New York), 8:30 AM PT (San Francisco), through Friday, December 11, 2009 by dialing +44 (0) 2081 961 998 (UK) or +1 866 583 1035 (US), and entering access code 8403264#.

Additional information:

Dr. William J. Polvino
Chief Operating Officer
+1 (917) 647 9107
wjp@lcpharma.com

Peter Schøtt Knudsen
General Counsel and Head of Investor Relations
+45 20 55 38 17
psk@lcpharma.com

The forward looking statements and targets contained herein are based on LifeCycle Pharma A/S' management's current view and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. LifeCycle Pharma A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless required by applicable law.

About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide®, currently on the U.S. market and a diversified near- and medium-term pipeline with four product candidates in clinical trials and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.



Executive Management's and the Board of Directors' Statement on the Interim Report

The Executive Management and the Board of Directors have considered and adopted the Interim Report of LifeCycle Pharma A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces. The group does not face any material risks or uncertainties relating to the financial statements.

Hørsholm, November 11, 2009

Executive Management

Peter G. Nielsen
Executive Vice President

Dr. William J. Polvino
Chief Operating Officer

Board of Directors

Paul Edick
(Chairman)

Thomas Dyrberg
(Deputy Chairman)

Kurt Anker Nielsen

Jean Deleage

Gérard Soula

Anders Götzsche

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Quarterly Numbers in DKK							
	Q3 2009 DKK'000	Q2 2009 DKK'000	Q1 2009 DKK'000	Q4 2008 DKK'000	Q3 2008 DKK'000	Q2 2008 DKK'000	Q1 2008 DKK'000
Income Statement							
Revenue	447	1,499	349	4,809	154,433	7,952	2,928
Research and development costs	(43,986)	(57,604)	(62,810)	(78,684)	(69,738)	(69,537)	(52,916)
Administrative expenses	(14,330)	(16,357)	(16,981)	(18,286)	(18,626)	(18,854)	(17,545)
One-off restructuring cost	(9,489)	-	-	-	-	-	-
Operating loss	(67,358)	(72,462)	(79,443)	(92,161)	66,069	(80,439)	(67,533)
Net financial income / (expenses)	394	(2,105)	9,735	11,507	5,150	5,305	2,323
Net loss for the period	(66,964)	(74,567)	(69,708)	(80,654)	71,219	(75,134)	(65,210)
Balance Sheet							
Cash and cash equivalents	392,133	439,809	520,228	600,130	666,895	588,001	265,501
Total assets	444,915	500,455	574,148	646,293	708,915	634,100	311,892
Share capital	56,568	56,439	56,439	56,288	56,288	56,093	32,105
Total equity	373,583	436,727	507,712	572,323	648,456	571,863	266,277
Investment in property, plant and equipment	890	7,149	2,515	1,358	1,205	3,207	801
Cash Flow Statement							
Cash flow from operating activities	(44,714)	(71,872)	(77,772)	(68,616)	80,250	(48,362)	(65,832)
Cash flow from investing activities	(843)	(7,064)	(2,600)	(1,415)	(1,205)	(3,207)	(801)
Cash flow from financing activities	(446)	2,593	(105)	(1,653)	463	373,930	897
Cash and cash equivalents at period end	392,133	439,809	520,228	600,130	666,895	588,001	265,501
Financial Ratios							
Basic and diluted EPS	(1.19)	(1.32)	(1.24)	(1.43)	1.27	(1.46)	(2.05)
Weighted average number of shares	56,467,878	56,438,320	56,297,561	56,287,507	56,135,241	51,611,713	31,833,188
Average number of employees (FTEs)	88	99	102	107	113	101	93
Assets/equity	1.19	1.15	1.13	1.13	1.09	1.11	1.17

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Quarterly Numbers in Euro							
	Q3 2009 EUR'000	Q2 2009 EUR'000	Q1 2009 EUR'000	Q4 2008 EUR'000	Q3 2008 EUR'000	Q2 2008 EUR'000	Q1 2008 EUR'000
Income Statement							
Revenue	60	201	47	645	20,745	1,068	393
Research and development costs	(5,908)	(7,738)	(8,438)	(10,569)	(9,368)	(9,341)	(7,108)
Administrative expenses	(1,925)	(2,197)	(2,281)	(2,456)	(2,502)	(2,532)	(2,357)
One-off restructuring cost	(1,275)	-	-	-	-	-	-
Operating loss	(9,048)	(9,734)	(10,672)	(12,380)	8,875	(10,805)	(9,072)
Net financial income / (expenses)	53	(283)	1,308	1,546	692	713	312
Net loss for the period	(8,995)	(10,017)	(9,364)	(10,834)	9,567	(10,093)	(8,760)
Balance Sheet							
Cash and cash equivalents	52,676	59,080	69,883	80,616	89,585	78,987	35,665
Total assets	59,766	67,227	77,126	86,817	95,229	85,179	41,897
Share capital	7,599	7,582	7,582	7,561	7,561	7,535	4,313
Total equity	50,184	58,666	68,201	76,881	87,108	76,819	35,769
Investment in property, plant and equipment	120	960	338	182	162	431	108
Cash Flow Statement							
Cash flow from operating activities	(6,006)	(9,655)	(10,447)	(9,217)	10,780	(6,497)	(8,843)
Cash flow from investing activities	(113)	(949)	(349)	(190)	(162)	(431)	(108)
Cash flow from financing activities	(60)	348	(14)	(222)	62	50,230	120
Cash and cash equivalents at period end	52,676	59,080	69,883	80,616	89,585	78,987	35,665
Financial Ratios							
Basic and diluted EPS	(0.16)	(0.18)	(0.17)	(0.19)	0.17	(0.20)	(0.28)
Weighted average number of shares	56,467,878	56,438,320	56,297,561	56,287,507	56,135,241	51,611,713	31,833,188
Average number of employees (FTEs)	88	99	102	107	113	101	93
Assets/equity	1.19	1.15	1.13	1.13	1.09	1.11	1.17

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Income Statement		Consolidated			
(DKK'000)	YTD 2009	YTD 2008	Q3 2009	Q3 2008	Year 2008
Revenue	2,294	165,313	447	154,433	170,122
Research and development costs	(164,400)	(192,191)	(43,986)	(69,738)	(270,875)
Administrative expenses	(47,668)	(55,025)	(14,330)	(18,626)	(73,311)
One-off restructuring cost	(9,489)	-	(9,489)	-	-
Operating loss	(219,263)	(81,903)	(67,358)	66,069	(174,064)
Financial income	19,733	18,422	1,889	7,714	45,474
Financial expenses	(11,709)	(5,644)	(1,495)	(2,564)	(21,189)
Loss before tax	(211,239)	(69,125)	(66,964)	71,219	(149,779)
Tax for the period	-	-	-	-	-
Net loss for the period	(211,239)	(69,125)	(66,964)	71,219	(149,779)
Basic and diluted EPS	(3.75)	(1.48)	(1.19)	1.27	(3.06)
Weighted average number of shares	56,401,877	46,561,782	56,467,878	56,135,241	49,006,500

Statement of comprehensive income		Consolidated			
(DKK'000)	YTD 2009	YTD 2008	Q3 2009	Q3 2008	Year 2008
Net loss for the period	(211,239)	(69,125)	(66,964)	71,219	(149,779)
Other comprehensive income:					
Currency translation differences	356	341	(12)	(276)	922
Other comprehensive income for the period	356	341	(12)	(276)	922
Total comprehensive income for the period	(210,883)	(68,784)	(66,976)	70,943	(148,857)

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Assets	Consolidated		
(DKK'000)	Sept. 30 2009	Sept. 30 2008	Dec. 31 2008
Licenses and rights	642	692	679
Intangible assets	642	692	679
Property, plant and equipment	20,835	21,420	20,628
Leasehold improvements	7,942	5,395	5,224
Property, plant and equipment	28,777	26,815	25,852
Non-current assets	29,419	27,507	26,531
Trade receivables	448	6,854	1,670
Other receivables	4,824	6,722	10,928
Prepayments	18,091	937	7,034
Receivables	23,363	14,513	19,632
Cash and cash equivalents	392,133	666,895	600,130
Current assets	415,496	681,408	619,762
Assets	444,915	708,915	646,293

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Equity & Liabilities	Consolidated		
(DKK'000)	Sept. 30 2009	Sept. 30 2008	Dec. 31 2008
Share capital	56,568	56,288	56,288
Share premium	1,080,253	1,079,214	1,078,740
Translation reserves	2,099	1,162	1,743
Retained earnings/loss	(765,337)	(488,208)	(564,448)
Equity	373,583	648,456	572,323
Provisions	10,492	10,492	10,492
Finance lease	15,465	17,094	16,082
Non-current liabilities	25,957	27,586	26,574
Finance lease	5,316	4,619	4,450
Trade payables	14,683	13,669	22,910
Other payables	25,376	14,585	20,036
Current liabilities	45,375	32,873	47,396
Liabilities	71,332	60,459	73,970
Equity and liabilities	444,915	708,915	646,293

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Cash Flow Statement	Consolidated				
(DKK'000)	YTD 2009	YTD 2008	Q3 2009	Q3 2008	Year 2008
Operating loss	(219,263)	(81,903)	(67,358)	66,069	(174,064)
Share-based payment	10,350	12,465	2,995	3,905	16,879
Depreciation and amortization	7,664	6,497	2,772	2,283	8,834
Changes in working capital	(2,974)	16,312	16,552	2,825	23,371
Cash flow from operating activities before interest	(204,223)	(46,629)	(45,039)	75,082	(124,980)
Financial items received	21,679	18,146	1,820	7,649	43,503
Financial items paid	(11,812)	(5,571)	(1,495)	(2,590)	(21,083)
Cash flow from operating activities	(194,356)	(34,054)	(44,714)	80,141	(102,560)
Purchase of property, plant and equipment	(10,555)	(5,212)	(890)	(1,205)	(6,571)
Cash transfer to restricted security deposit	48	-	47	-	(57)
Cash flow from investing activities	(10,507)	(5,212)	(843)	(1,205)	(6,628)
Installments on bank borrowings and finance lease	248	(3,795)	(1,285)	(1,281)	(4,975)
Proceeds from issuance of shares, net	1,793	379,085	839	1,744	378,612
Cash flow from financing activities	2,041	375,290	(446)	463	373,637
Increase/(decrease) in cash and cash equivalents	(202,822)	336,024	(46,003)	79,399	264,449
Cash and cash equivalents at beginning of period	598,735	330,402	438,415	586,746	330,402
Exchange gains/(losses) on cash and cash equivalent	(5,128)	(919)	(1,627)	(638)	3,884
Cash and cash equivalents at end of period	390,785	665,507	390,785	665,507	598,735
Cash and cash equivalents at end of period comprise:					
Restricted bank deposit	1,348	1,388	1,348	1,388	1,395
Deposit on demand and cash	390,785	665,507	390,785	665,507	598,735
	392,133	666,895	392,133	666,895	600,130

Interim Report
for the 9 Months Ended September 30, 2009
(November 11, 2009)



Consolidated Equity						
	Number of Shares	Share Capital DKK'000	Share Premium DKK'000	Translation Reserves DKK'000	Retained Earnings DKK'000	Total DKK'000
Equity as of January 1, 2008	31,770,705	31,771	724,645	821	(431,548)	325,689
Total comprehensive income				341	(69,125)	(68,784)
Issuance of shares	23,987,771	23,988	383,804			407,792
Warrant exercises	529,031	529	3,560			4,089
Share-based payment					12,465	12,465
Costs related to capital increases			(32,795)			(32,795)
Equity as of September 30, 2008	56,287,507	56,288	1,079,214	1,162	(488,208)	648,456
Total comprehensive income				581	(80,654)	(80,073)
Share-based payment					4,414	4,414
Costs related to capital increases			(474)			(474)
Equity as of December 31, 2008	56,287,507	56,288	1,078,740	1,743	(564,448)	572,323
Total comprehensive income				356	(211,239)	(210,883)
Warrant exercises	280,303	280	1,523			1,803
Share-based payment					10,350	10,350
Costs related to capital increases			(10)			(10)
Equity as of September 30, 2009	56,567,810	56,568	1,080,253	2,099	(765,337)	373,583

The share capital is not available for distribution, while other reserves are distributable for dividend purposes subject to the provision of the Danish Public Company Act.